These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20259524)

  • 1. Polymyxin: a new chemotherapeutic agent.
    STANSLY PG; SHEPHERD RG; WHITE HJ
    Bull Johns Hopkins Hosp; 1947 Jul; 81(1):43-54. PubMed ID: 20259524
    [No Abstract]   [Full Text] [Related]  

  • 2. Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins.
    Lu X; Chan T; Xu C; Zhu L; Zhou QT; Roberts KD; Chan HK; Li J; Zhou F
    J Antimicrob Chemother; 2016 Feb; 71(2):403-12. PubMed ID: 26494147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosynthesis of Polymyxins B, E, and P Using Genetically Engineered Polymyxin Synthetases in the Surrogate Host Bacillus subtilis.
    Kim SY; Park SY; Choi SK; Park SH
    J Microbiol Biotechnol; 2015 Jul; 25(7):1015-25. PubMed ID: 26059516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical use of the polymyxins: the tale of the fox and the cat.
    Wenzler E; Bunnell KL; Danziger LH
    Int J Antimicrob Agents; 2018 May; 51(5):700-706. PubMed ID: 29305954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.
    van der Heijden IM; Levin AS; De Pedri EH; Fung L; Rossi F; Duboc G; Barone AA; Costa SF
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():8. PubMed ID: 17697363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Structure-functional studies of polymyxins. (1)-NMR analysis of polymyxin B and M conformation].
    Okhanov VV; Dubovskiĭ PV; Miroshnikov AI
    Bioorg Khim; 1991 Dec; 17(12):1689-93. PubMed ID: 1667724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular Uptake and Localization of Polymyxins in Renal Tubular Cells Using Rationally Designed Fluorescent Probes.
    Yun B; Azad MA; Nowell CJ; Nation RL; Thompson PE; Roberts KD; Velkov T; Li J
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7489-96. PubMed ID: 26392495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinations of antimicrobial agents: II. The in vitro sensitivity of 52 strains of proteus species to sulphafurazole, polymyxins and combinations of sulphafurazole and polymyxins.
    Kuipers JS
    Arch Chir Neerl; 1976; 28(1):33-41. PubMed ID: 180905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic combinations of polymyxins.
    Lenhard JR; Nation RL; Tsuji BT
    Int J Antimicrob Agents; 2016 Dec; 48(6):607-613. PubMed ID: 27865626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Separation and microbiological determination of polymyxin, neomycin and a nitrofuran chemotherapeutic agent].
    Veronese M; Marca G
    Farmaco Prat; 1970 Jul; 25(7):428-34. PubMed ID: 4319293
    [No Abstract]   [Full Text] [Related]  

  • 11. Imaging the distribution of polymyxins in the kidney.
    Yun B; Azad MA; Wang J; Nation RL; Thompson PE; Roberts KD; Velkov T; Li J
    J Antimicrob Chemother; 2015 Mar; 70(3):827-9. PubMed ID: 25377569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the Polymyxin D Synthetase Biosynthetic Cluster and Product Profile of Paenibacillus polymyxa ATCC 10401.
    Galea CA; Han M; Zhu Y; Roberts K; Wang J; Thompson PE; L J; Velkov T
    J Nat Prod; 2017 May; 80(5):1264-1274. PubMed ID: 28463513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical considerations for optimal use of the polymyxins: A focus on agent selection and dosing.
    Pogue JM; Ortwine JK; Kaye KS
    Clin Microbiol Infect; 2017 Apr; 23(4):229-233. PubMed ID: 28238870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of polymyxin B and E (colistin) on blood coagulation, thrombocyte function, and fibrin structure (author's transl)].
    Klingemann HG; Egbring R; Kaffarnik H
    Arzneimittelforschung; 1980; 30(10):1719-21. PubMed ID: 6254544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse reactions associated with systemic polymyxin therapy.
    Justo JA; Bosso JA
    Pharmacotherapy; 2015 Jan; 35(1):28-33. PubMed ID: 25266910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections.
    Brown P; Dawson MJ
    J Antibiot (Tokyo); 2017 Apr; 70(4):386-394. PubMed ID: 28074057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymyxins: wisdom does not always come with age.
    Kassamali Z; Rotschafer JC; Jones RN; Prince RA; Danziger LH
    Clin Infect Dis; 2013 Sep; 57(6):877-83. PubMed ID: 23728146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibacterial mechanisms of polymyxin and bacterial resistance.
    Yu Z; Qin W; Lin J; Fang S; Qiu J
    Biomed Res Int; 2015; 2015():679109. PubMed ID: 25664322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility testing of the polymyxins: where are we now?
    Humphries RM
    Pharmacotherapy; 2015 Jan; 35(1):22-7. PubMed ID: 25329490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens.
    Cheah SE; Johnson MD; Zhu Y; Tsuji BT; Forrest A; Bulitta JB; Boyce JD; Nation RL; Li J
    Sci Rep; 2016 May; 6():26233. PubMed ID: 27195897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.